Varian Grows Cancer Portfolio With Endocare & Alicon Acquisitions
Varian is expanding its cancer care solutions portfolio with two new acquisitions in the interventional oncology space. The medtech giant said it will pay $185m to buy Endocare Systems, based in Austin, Texas; and Alicon, based in Hangzhou, China.
You may also be interested in...
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.
Radiation oncology firm Varian believes Sirtex will allow it to expand into additional areas of cancer treatment.